Global Progesterone Market Poised for Significant Growth: Projected to Reach USD 4.80 Billion by 2034

After extensive research, the global progesterone market suggests an upward trajectory from 2024 to 2034, inferring a healthy CAGR of 12.30%. With preliminary valuations of USD 1.50 billion in 2024, the sales revenue of progesterone is assumed to surge to USD 4.80 billion by 2034.

The progesterone market thrives because of the rising cases of breast cancer, AIDS, and amenorrhea and the adoption of progesterone in medicating the issues. Several researchers infer that progesterone and estradiol together aid in regulating various medical disorders like human immunodeficiency virus (HIV).

Sample Report Copy: https://www.futuremarketinsights.com/reports/sample/rep-gb-19526

According to the World Health Organization reports in 2021, around 38.4 million people were infected with HIV. For breast cancer treatment, hormone therapy is constrained to cases that show the prevalence of receptors for progesterone and estrogen.

The progesterone and estrogen market envisions higher growth opportunities because of the surging investments and the research and development practices of private research establishments and government institutions to reveal better usages of hormone therapy. There are diverse ongoing investigations to evaluate the influence of progesterone in postmenopausal women.

The progesterone industry witnesses growth constraints because of the side effects encountered after its treatment. Some prevalent side effects are weight fluctuations, increased face and body hair, headache, persistent breast tenderness, and baldness. Though these symptoms do not seem grave, yet they can become serious if the progesterone treatment is not done in a disciplined and experienced environment.

Regional Outlook:

North America is slated to garner a considerable share of the progesterone market, because of the amplifying resilience of modern treatments. A catalyst to the growth is the foresighted approach of progesterone vendors, who are undertaking joint efforts to strengthen their research and development abilities. This strategy is in response to the escalating demand for progesterone, which is spurred by the high disease burden, such as rising cases of kidney, and breast cancer and a soaring population of menopausal women.

“The progesterone demand is slated to witness growth owing to spurring demand from health protection sectors worldwide. Factors like soaring consciousness of women’s health and development in pharmaceuticals strengthen progesterone market expansion.”, says an FMI analyst.

For More Information or Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-19526

Key Takeaways:

• The natural segment in the formulation category is set to grab a share of 62.00% in 2024.
• In the route of administration category, the injectable segment is set to acquire a market share of 38.20% in 2024.
• The United States progesterone industry implies augmentation at a CAGR of 12.60% between 2024 and 2034.
• The United Kingdom progesterone market indicates a CAGR of 13.70% through 2034.
• Chinese market infers a CAGR of 13.20% through 2034.
• Japan’s sale of progesterone indicates a CAGR of 14.10% through 2034.
• South Korean progesterone market reflects expansion between 2024 and 2034 at a CAGR of 14.70%.

Competitive Landscape:

Prominent progesterone vendors are striving to dominate the market. The industry is set to experience a considerable upsurge in integrated progesterone companies and an amplified presence for regional brands, booming their market share. The progesterone providers adopt novel technologies, research and development, and expansions to augment their position.

Latest Evolutions:

• In September 2022, the Scottish Medicines Consortium commenced the usage of BIJUVE (1mg Estradiol/100mg Progesterone) across the NHS. Theramex’s Bijuve® is the first body-identical hormone replacement therapy (HRT) signified for estrogen insufficiency traits in postmenopausal women.
• In May 2023, the FDA sanctioned Veozah, a drug made to curb symptoms like flushing and sweating undergone by women with low estrogen levels.

Key Market Players

• Alkem Laboratories Ltd
• Aquatic Group
• Bionpharma Inc.
• Cadila Pharmaceuticals
• Cipla Inc.

A Detailed Full Report: https://www.futuremarketinsights.com/checkout/19526

Key Segments:

By Formulation:

• Natural
• Synthetic

By Route of Administration:

• Injectable
• Oral
• Transdermal
• Other

By Application:

• Menopause
• Contraception
• Dysfunctional Uterine Bleeding
• Hyperplastic Precursor Lesions
• Endometrial Cancer
• Other

By Drug Type:

• Branded
• Generic

By Type:

• Prescription
• OTC

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube